Pfizer Inc. (PFE) Position Raised by Capital Analysts LLC

Capital Analysts LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 6.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 30,926 shares of the biopharmaceutical company’s stock after buying an additional 1,813 shares during the period. Capital Analysts LLC’s holdings in Pfizer were worth $1,005,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. First Hawaiian Bank boosted its position in Pfizer by 0.3% in the third quarter. First Hawaiian Bank now owns 8,585 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 24 shares during the period. Peregrine Asset Advisers Inc. boosted its position in Pfizer by 0.5% in the fourth quarter. Peregrine Asset Advisers Inc. now owns 7,287 shares of the biopharmaceutical company’s stock worth $237,000 after buying an additional 33 shares during the period. Ronna Sue Cohen boosted its position in Pfizer by 0.4% in the third quarter. Ronna Sue Cohen now owns 7,916 shares of the biopharmaceutical company’s stock worth $268,000 after buying an additional 35 shares during the period. Alpha Windward LLC boosted its position in Pfizer by 0.5% in the third quarter. Alpha Windward LLC now owns 8,315 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 40 shares during the period. Finally, Brick & Kyle Associates boosted its position in Pfizer by 0.7% in the third quarter. Brick & Kyle Associates now owns 11,319 shares of the biopharmaceutical company’s stock worth $383,000 after buying an additional 74 shares during the period. Institutional investors and hedge funds own 69.53% of the company’s stock.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Shares of Pfizer Inc. (NYSE:PFE) opened at 34.38 on Tuesday. The firm has a market capitalization of $204.63 billion, a P/E ratio of 29.31 and a beta of 0.94. Pfizer Inc. has a 12 month low of $29.17 and a 12 month high of $37.39. The firm’s 50-day moving average is $33.34 and its 200 day moving average is $32.84.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $0.47 EPS for the quarter, missing the consensus estimate of $0.50 by $0.03. The business had revenue of $13.60 billion for the quarter, compared to the consensus estimate of $13.64 billion. Pfizer had a return on equity of 23.18% and a net margin of 13.50%. The company’s revenue was down 3.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.53 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post $2.55 EPS for the current year.

Your IP Address:

A number of equities analysts have issued reports on PFE shares. Barclays PLC upgraded Pfizer from an “equal weight” rating to an “overweight” rating and set a $38.00 target price for the company in a report on Tuesday, November 29th. BMO Capital Markets set a $33.00 target price on Pfizer and gave the stock a “hold” rating in a report on Wednesday, November 30th. Guggenheim started coverage on Pfizer in a report on Friday, December 2nd. They set a “neutral” rating for the company. Sanford C. Bernstein reiterated an “overweight” rating on shares of Pfizer in a report on Wednesday, December 7th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $30.00 target price on shares of Pfizer in a report on Monday, December 19th. Thirteen research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $37.32.

In other news, insider Rady A. Johnson sold 4,500 shares of the business’s stock in a transaction dated Friday, March 10th. The shares were sold at an average price of $34.19, for a total transaction of $153,855.00. Following the completion of the sale, the insider now directly owns 54,963 shares of the company’s stock, valued at $1,879,184.97. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Mikael Dolsten sold 30,970 shares of the business’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $34.51, for a total transaction of $1,068,774.70. Following the sale, the insider now directly owns 64,719 shares of the company’s stock, valued at $2,233,452.69. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,470 shares of company stock valued at $2,449,150. 0.07% of the stock is currently owned by insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.

5 Day Chart for NYSE:PFE

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply